Helicos BioSciences Corporation

Helicos Biosciences Prices Initial Public Offering

Helicos Biosciences Prices Initial Public Offering

May 24, 2007

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Helicos BioSciences Corporation (Nasdaq: HLCS) announced today that it has priced its initial public offering of 5,400,000 shares of common stock at $9.00 per share. All of the common stock is being offered by the company, and the common stock will trade on the NASDAQ Global Market under the symbol "HLCS." The company has granted the underwriters an option to purchase up to an additional 810,000 shares to cover over-allotments, if any.

Mascoma Corporation

Mascoma Corporation Adds Former Senator Tom Daschle to Board of Directors

Mascoma Corporation Adds Former Senator Tom Daschle to Board of Directors

June 4, 2007

Long Time Ethanol Industry Advocate Brings Leadership Experience to Mascoma

LS9

Building Better Biofuels:Startup LS9 is developing microbes that produce hydrocarbons

Building Better Biofuels:Startup LS9 is developing microbes that produce hydrocarbons

June 6, 2007

Wednesday, June 06, By Neil Savage

The U.S. Department of Energy has set a goal of replacing 30 percent of gasoline used in the United States with fuels from renewable biological sources by 2030, and President Bush has made ethanol production a priority. So it is hardly surprising that some biotech startup companies are positioning themselves to take advantage of an anticipated booming market for biofuels.

LS9

Renewable Petroleum Company LS9 Announces Distinguished Hire

Renewable Petroleum Company LS9 Announces Distinguished Hire

June 18, 2007

SAN CARLOS, Calif., June 18 /PRNewswire/ -- LS9, the Renewable Petroleum Company (TM), today announced that it has named Dr. Fernando Valle as its Senior Director of Metabolic Engineering, a key position in its effort to commercially deliver a clean, renewable petroleum substitute. LS9 will offer a broad portfolio of DesignerBiofuels (TM) products that are lab-engineered for various commercial end-uses, including custom, fit-for-purpose gasoline, diesel, and jet fuel formulations.

AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals CEO Tuan Ha-Ngoc Receives Ernst & Young New England Entrepreneur Of The Year® Award

AVEO Pharmaceuticals CEO Tuan Ha-Ngoc Receives Ernst & Young New England Entrepreneur Of The Year® Award

June 18, 2007

CAMBRIDGE, MA, June 18, 2007 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that its president and chief executive officer, Tuan Ha-Ngoc, has been awarded the Ernst & Young New England Entrepreneur of the Year® in the life sciences category.

Helicos BioSciences Corporation

Helicos BioSciences Strengthens Executive Management Team in Preparation for Commercial Launch

Helicos BioSciences Strengthens Executive Management Team in Preparation for Commercial Launch

June 19, 2007

 CAMBRIDGE, Mass., Jun 19, 2007 (BUSINESS WIRE) -- Helicos BioSciences Corporation (NASDAQ: HLCS) announced today the addition of new members to its executive management team as a key step in building a commercial organization. Chip Leveille has been appointed Vice President of Sales and Marketing and Mark Solakian has been named Vice President and General Counsel.

Color Kinetics

Color Kinetics Announces Acquisition by Philips

Color Kinetics Announces Acquisition by Philips

June 19, 2007

Intelligent LED lighting pioneer joins global lighting leader

Mascoma Corporation

Mascoma Corporation Names James Flatt Senior Vice President of Research and Development

Mascoma Corporation Names James Flatt Senior Vice President of Research and Development

June 20, 2007

To Apply Fermentation Research and Strain Development Expertise

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mascoma Corporation, a leader in low-carbon cellulosic biomass-to-ethanol development and production, today named James H. Flatt, Ph.D. as Senior Vice President, Research and Development. In this position, Dr. Flatt will lead the company’s initiatives to develop environmentally beneficial and cost-effective technologies to convert cellulosic biomass into ethanol.

Helicos BioSciences Corporation

Helicos BioSciences Announces Commencement of Commercial Manufacturing

Helicos BioSciences Announces Commencement of Commercial Manufacturing

June 25, 2007

Industry Expert, William Cotter, Joins Helicos as Vice President of Operations

Epitome Biosystems

Epitome Biosystems Initiates Second Partnership with EMD Chemicals for Commercial Products

Epitome Biosystems Initiates Second Partnership with EMD Chemicals for Commercial Products

July 10, 2007

Waltham, MA, July 10, 2007 – Epitome Biosystems announced today a second licensing and development agreement with EMD Chemicals Inc., an affiliate of Merck KGaA of Germany, using Epitome’s EpiTag™ technology. The partnership will focus on developing EpiTag™ assays for the quantitative measurement of various targets, including membrane proteins. Products will be manufactured, marketed and sold worldwide for research applications by EMD through its well-known Novagen® brand. Sample analysis will be available as a service from Epitome.